"Hyloris Pharmaceuticals has received a complete response letter from the @US_FDA, seeking clarification on one topic related to its registration of Maxigesic IV. #HylorisPharma #FDA #BioSpace https://t.co/XJhU64eUyR" (,@biospace) Jul 1, 2022
Clinical • FDA event
|